Reputation how can you have an impact? Stefaan Fiers, PhD - - PDF document

▶

Dec 24, 2023 278 likes •392 views

(C)St. Fiers - BeAPP presentation 2/3/2018 Reputation how can you have an impact? Stefaan Fiers, PhD Communications & Public Policy Director, pharma.be ste_fiers pharmabe While we are all patient centric 1 (C)St. Fiers - BeAPP

SLIDE 1

(C)St. Fiers - BeAPP presentation 2/3/2018 1

Reputation – how can you have an impact?

Stefaan Fiers, PhD Communications & Public Policy Director, pharma.be ste_fiers pharmabe

While we are all patient centric

SLIDE 2

(C)St. Fiers - BeAPP presentation 2/3/2018 2

Instead, we can help to refocus the debate

n
Our mission
Medical progress
Health is wealth
Health in all policies
CSR
…

The value of medicines

Our mission : More than 7,000 treatments in development

SLIDE 3

(C)St. Fiers - BeAPP presentation 2/3/2018 3

The benefit of medical & pharmaceutical progress

Medicines are some of the most powerful tools in treating and curing deadly diseases

Hepatitis C Virus (HCV): HCV, which is the leading cause of liver transplants and the reason liver

cancer is on the rise, is now curable in more than 90% of treated patients with only 8-12 weeks of treatment.

* Treatment duration. Note: EMA approval dates. Cure rates are based on the results of clinical trials reported by the US Food and Drug Administration (FDA) for different drugs against Hepatitis C. Source: Health Advances analysis; 1Hope 2014 Prevalence and estimation of hepatitis B and C infections in the WHO European region Epidemiol Infect; European Medicines Agency (EMA) website; 2EFPIA 2015 Health & Growth Evidence Compendia analysis

f PhRMA 2014 25 Years of Progress Against Hepatitis C and PhRMA 2015 Pharma Profile.

0% 25% 50% 75% 100%

1st generation (2001-2010) Interferon and Ribavarin 2nd generation (2011-2013) Protease Inhibitors 3rd generation (2013-2014) Polymerase Inhibitors 4th generation (2014-2015) Combination Therapies

Cure Rate

41%

cure rate

63-80%

cure rate

90%

cure rate

95-96%

cure rate

+133% cure rate increase for patients2

48 Weeks* 24-48 Weeks* 12 Weeks* 8-12 Weeks* 1st generation (1999-2010) Interferon and Ribavarin (IFN-R) Injection 2nd generation (2011-2013) Protease Inhibitors w/ IFN Injection 3rd generation (2013-2014) Polymerase Inhibitors w/ IFN Injection 4th generation (2014- 2015) Oral Combination Therapies

15 million

people are living with Hepatitis C in Europe1

SLIDE 4

(C)St. Fiers - BeAPP presentation 2/3/2018 4

R&D is very capital intensive

The development of a medicine is long, demanding and risky.

A new medicine can be developed within 10 to 15 years. Resources are needed today to fund R&D-activities for new and wanted medicines in the future.

SLIDE 5

(C)St. Fiers - BeAPP presentation 2/3/2018 5

The pharma business model

Obtaining the required resources, from sales and investors, to invest and take risks

n a long term in order to allow innovation. This is at the core of the pharma

business model.

Profits?
Yes.
Why?

SLIDE 6

(C)St. Fiers - BeAPP presentation 2/3/2018 6

Profits in the pharmaceutical industry are not out of line with comparable high risk knowledge-intensive sectors.

pharma is only 13% of the healthcare budget and contributes most to savings

SLIDE 7

(C)St. Fiers - BeAPP presentation 2/3/2018 7

The pharma valley in Belgium

A unique ecosystem of multinational corporations, biotechnological companies and specialist SMEs

2 airports with CEIV certification: Brussels & Liège

pharma.be members only

Pharma figures 2016 : Belgium, a growing pharmaceutical hub

SLIDE 8

(C)St. Fiers - BeAPP presentation 2/3/2018 8

Belgium, a European leader in pharma

2nd in R&D spending 4th in pharma employment 2nd in export of medicines 2nd in R&D employment €2,89 Bn 4.472 researchers 35.250 employees € 40,7 Bn

Weighting based on the relative share of each country in the total EU population 16

Belgium, #2 in EU in clinical research

Belgium holds a remarkable position in the EU, with: Belgium is at the forefront of novel medical techniques, with:

SLIDE 9

(C)St. Fiers - BeAPP presentation 2/3/2018 9

#WijGevenNietOp – #LeCombatContinue

SLIDE 10

(C)St. Fiers - BeAPP presentation 2/3/2018 10

#We Wont Rest – are you?

Please join us in this campaign
And become a proud ambassador of the pharma industry
Send your picture
and your ‘pledge’ (max 250 characters)

to Gregory Willocq of pharma.be gw@pharma.be #LeCombatContinue -#WijGevenNietOp

Like us, share our info

pharmabe ste_fiers

https://www.linkedin.com/company/pharma-be/

SLIDE 11

(C)St. Fiers - BeAPP presentation 2/3/2018 11

Thank you !

e: sf@pharma.be m: 0476-769077 t: ste_fiers